Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Drug:  sunitinib malate
Find trials that include:  Any drugs shown
Results 1-20 of 20 for your search:
Start Over
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A6181202, NCI-2014-00456, 2011-004363-74, NCT01525550
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-214, NCI-2014-01993, 2014-001750-42, NCT02231749
A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advance Renal Cell Carcinoma [IMmotion151]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29637, NCI-2015-01390, 2014-004684-20, NCT02420821
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-04, NCI-2015-00740, NCT02386111
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Targeted Enzyme Inhibitor Therapy in Treating Patients with Advanced Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0096, NCI-2013-01478, 110096, P10782, 8639, NCT01306045
Sunitinib Malate or Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 20
Trial IDs: 11-C-0200, NCI-2013-01496, 110200, P11836, P8875_A21PAMDREVW01, 8875, NCT01391962
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 21
Trial IDs: A6181196, NCI-2014-00205, 2011-002008-33, NCT01396148
Alternating Sunitinib Malate and Temsirolimus Therapy in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: D1011, NCI-2011-03505, NCT01517243
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: 7195, NCI-2012-01084, CA180-392, NCT01620216
Sunitinib Malate in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Never Smoked
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-086, NCI-2013-01116, NCT01829217
Sunitinib Malate on an Alternative Schedule in Treating in Patients with Metastatic Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0944, NCI-2014-01908, NCI-2014-01171, NCT02060370
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13P.377, NCI-2014-00338, 2013-047, NCT02068586
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 150040, 339636, P141605, NCT02315625
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, EAY131-A, EAY131-B, EAY131-E, EAY131-F, EAY131-G, EAY131-H, EAY131-Q, EAY131-R, EAY131-U, EAY131-V, NCT02465060
A Rollover Protocol for Subjects Previously Treated With AGS-003
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AGS-003-005, NCI-2011-03808, NCT01482949
Sunitinib Malate Alternating with Regorafenib in Treating Patients with Gastrointestinal Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-149, NCI-2014-02033, ONC-2013-024, WI186553, NCT02164240
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: A6181036, NCI-2010-01834, NCT00094029
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: A6181037, NCI-2013-01674, NCT00130897
Start Over